New combo therapy shows promise for rare, Tough-to-Treat leukemia

NCT ID NCT05901974

Recruiting now Disease control Sponsor: Sheng-Li Xue, MD Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether combining venetoclax and azacitidine can help people with a rare type of leukemia called acute leukemia of ambiguous lineage. The study will enroll 23 newly diagnosed patients aged 15 and older. The goal is to see if this drug combination can improve remission rates and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax and azacitidine
What this could lead to: If this works, it could offer a new, more effective treatment option for people with this rare and aggressive leukemia, potentially improving remission rates.
What could go wrong: This is a small, early-phase trial with only 23 participants, so results may not apply to everyone. The drugs can cause side effects like low blood counts and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute leukemia of ambiguous lineage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE

Contacts and locations

Locations

The First Affliated Hospital of Soochow University
RECRUITING

Suzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.